Analysts Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Target Price at $5.00

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Get Free Report) has been given a consensus rating of "Hold" by the five brokerages that are currently covering the firm, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $3.33.

Several research firms have recently weighed in on SYRS. TD Cowen reiterated a "hold" rating on shares of Syros Pharmaceuticals in a research note on Wednesday. JMP Securities reiterated a "market perform" rating on shares of Syros Pharmaceuticals in a research note on Wednesday. StockNews.com lowered Syros Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, November 4th. HC Wainwright restated a "neutral" rating and set a $1.00 price target (down from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday. Finally, Brookline Capital Management restated a "hold" rating on shares of Syros Pharmaceuticals in a research report on Wednesday.

Insider Transactions at Syros Pharmaceuticals

In other news, CFO Jason Haas bought 45,344 shares of Syros Pharmaceuticals stock in a transaction dated Thursday, September 12th. The stock was bought at an average cost of $1.68 per share, for a total transaction of $76,177.92. Following the purchase, the chief financial officer now directly owns 124,552 shares in the company, valued at approximately $209,247.36. This represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO Jason Haas purchased 45,344 shares of the business's stock in a transaction on Thursday, September 12th. The stock was acquired at an average price of $1.68 per share, for a total transaction of $76,177.92. Following the purchase, the chief financial officer now owns 124,552 shares of the company's stock, valued at approximately $209,247.36. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Conley Chee purchased 50,000 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was bought at an average cost of $1.51 per share, for a total transaction of $75,500.00. Following the acquisition, the chief executive officer now directly owns 72,504 shares in the company, valued at $109,481.04. This trade represents a 200.00 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 130,707 shares of company stock valued at $206,491. Corporate insiders own 12.26% of the company's stock.

Institutional Investors Weigh In On Syros Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Syros Pharmaceuticals by 21.3% in the first quarter. Vanguard Group Inc. now owns 928,046 shares of the company's stock worth $4,965,000 after purchasing an additional 163,234 shares during the last quarter. Acadian Asset Management LLC bought a new position in Syros Pharmaceuticals in the first quarter worth approximately $91,000. Kennedy Capital Management LLC bought a new position in Syros Pharmaceuticals in the first quarter worth approximately $2,166,000. Virtu Financial LLC bought a new position in Syros Pharmaceuticals in the first quarter worth approximately $64,000. Finally, Opaleye Management Inc. raised its position in Syros Pharmaceuticals by 119.1% in the first quarter. Opaleye Management Inc. now owns 787,545 shares of the company's stock worth $4,213,000 after acquiring an additional 428,175 shares during the period. Hedge funds and other institutional investors own 91.47% of the company's stock.

Syros Pharmaceuticals Stock Down 86.8 %

Shares of NASDAQ:SYRS traded down $2.37 during mid-day trading on Wednesday, hitting $0.36. 37,721,035 shares of the company traded hands, compared to its average volume of 463,847. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.25 and a current ratio of 2.25. Syros Pharmaceuticals has a 52-week low of $0.35 and a 52-week high of $8.17. The firm's 50 day simple moving average is $2.07 and its 200 day simple moving average is $3.84. The firm has a market cap of $9.66 million, a P/E ratio of -0.12 and a beta of 1.59.

Syros Pharmaceuticals (NASDAQ:SYRS - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) EPS for the quarter, topping analysts' consensus estimates of ($0.76) by $0.08. During the same period in the prior year, the company posted ($1.35) earnings per share. On average, equities analysts anticipate that Syros Pharmaceuticals will post -2.94 EPS for the current year.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.